Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 11/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CCR5 | P51681 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | AKT1 | P31749 | 2/20 | 0.35 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.35 |
| ▸ | PHLPP1 | O60346 | 1/20 | 0.35 |
| ▸ | ILK | Q13418 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14037240 | 0.84 | LMNA (0.37) | ALOX5PTGS1PTGS2CYP1A2CYP3A4 | |
| SCHEMBL14283908 | 0.83 | ALOX5 (0.41) | ALOX5PTGS1PTGS2CCR5PDE4D | |
| SCHEMBL14283912 | 0.83 | PDE4D (0.38) | ALOX5CCR5PDE4DMALT1LMNA | |
| SCHEMBL4468225 | 0.82 | ALOX5 (0.47) | ALOX5PTGS1PTGS2CYP1A2CYP3A4 | |
| SCHEMBL6027939 | 0.81 | ALOX5 (0.58) | ALOX5AKT1PDPK1PHLPP1ILK | |
| SCHEMBL6028033 | 0.81 | ALOX5 (0.58) | ALOX5AKT1PDPK1PHLPP1ILK | |
| SCHEMBL6463246 | 0.81 | ALOX5 (0.58) | ALOX5AKT1PDPK1PHLPP1ILK | |
| SCHEMBL5775188 | 0.81 | CYP1A2 (0.36) | ALOX5PTGS1PTGS2CYP1A2CYP3A4 | |
| SCHEMBL20822182 | 0.81 | ALOX5 (0.44) | ALOX5PTGS1PTGS2CYP1A2CYP3A4 | |
| SCHEMBL6027877 | 0.80 | ALOX5 (0.47) | ALOX5PTGS1PTGS2CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250043085-A1 | STABILISATION OF POLYISOBUTENE | BASF SE (DE) | 2025-02-06 | — | — | US | claimed |
| EP-4448638-A1 | STABILISATION OF POLYISOBUTENE | BASF SE (DE) | 2024-10-23 | — | — | EP | claimed |
| CN-118401596-A | Stabilization of polyisobutene | 巴斯夫欧洲公司 | 2024-07-26 | — | — | CN | claimed |
| WO-2023110570-A1 | STABILISATION OF POLYISOBUTENE | BASF SE (DE) | 2023-06-22 | — | — | WO | claimed |
| US-20160324823-A1 | TREATMENT OF MITOCHONDRIAL DISEASES | BIOELECTRON TECHNOLOGY CORPORATION | 2016-11-10 | — | — | US | claimed |
| US-20130267538-A1 | TREATMENT OF MITOCHONDRIAL DISEASES | GALILEO PHARMACEUTICALS INC. | 2013-10-10 | — | — | US | claimed |
| US-20070129564-A1 | Method for the production of (meth)acrylic acid esters | BASF AKTIENGESELLSCHAFT (DE) | 2007-06-07 | — | — | US | claimed |
| EP-1727780-A1 | PROCESS FOR PREPARING (METH)ACRYLIC ESTERS. | BASF AKTIENGESELLSCHAFT (DE) | 2006-12-06 | — | — | EP | claimed |
| WO-2005082828-A1 | METHOD FOR THE PRODUCTION OF (METH)ACRYLIC ACID ESTERS | BASF AKTIENGESELLSCHAFT (DE) | 2005-09-09 | — | — | WO | claimed |
| WO-2005032544-A1 | TREATMENT OF MITOCHONDRIAL DISEASES | GALILEO PHARMACEUTICALS, INC. (US) | 2005-04-14 | — | — | WO | claimed |
| US-20050065099-A1 | Alzheimer's disease; Parkinson's disease; brain disorders; antiepileptic agents; amyotrophic lateral sclerosis; vision defects | EDISON PHARMACEUTICALS, INC. | 2005-03-24 | — | — | US | claimed |
| US-20250043085-A1 | STABILISATION OF POLYISOBUTENE | BASF SE (DE) | 2025-02-06 | — | — | US | disclosed |
| EP-4448638-A1 | STABILISATION OF POLYISOBUTENE | BASF SE (DE) | 2024-10-23 | — | — | EP | disclosed |
| CN-118401596-A | Stabilization of polyisobutene | 巴斯夫欧洲公司 | 2024-07-26 | — | — | CN | disclosed |
| WO-2023110570-A1 | STABILISATION OF POLYISOBUTENE | BASF SE (DE) | 2023-06-22 | — | — | WO | disclosed |
| WO-2005032544-A1 | TREATMENT OF MITOCHONDRIAL DISEASES | GALILEO PHARMACEUTICALS, INC. (US) | 2005-04-14 | — | — | WO | disclosed |
| US-20050065099-A1 | Alzheimer's disease; Parkinson's disease; brain disorders; antiepileptic agents; amyotrophic lateral sclerosis; vision defects | EDISON PHARMACEUTICALS, INC. | 2005-03-24 | — | — | US | disclosed |
| US-6756432-B2 | POLYBUTADIENE TYPE POLYMER WITH A 1-BENZOPYRAN, A 1-BENZO PYRAN-2-ONE OR A BENZOIN DERIVATIVE; MOLDS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2004-06-29 | — | — | US | disclosed |
| US-20030153655-A1 | Polybutadiene composition | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-08-14 | — | — | US | disclosed |
| US-6465548-B1 | 6-HYDROXYCHROMAN DERIVATIVE WITH PHOSPHORUS AND PHENOLIC ANTIOXIDANTS; HEAT, LIGHT AND OXIDATION STABILITY DURING MOLDING | YOSHITOMI FINE CHEMICALS, LTD. (JP) | 2002-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129564-A1 | Method for the production of (meth)acrylic acid esters | MMAB, ACR, MCCC2 | ALOX5 378/4885PTGS1 861/4885PTGS2 1000/4885 |
| US-20050065099-A1 | Alzheimer's disease; Parkinson's disease; brain disorders; antiepileptic agents; amyotrophic lateral sclerosis; vision defects | CLN6, LDHA, NLN | ALOX5 1992/4885PTGS1 3200/4885PTGS2 3398/4885 |
| US-20160324823-A1 | TREATMENT OF MITOCHONDRIAL DISEASES | NLN, FH, MFN2 | ALOX5 1604/4885PTGS1 2790/4885PTGS2 2651/4885 |
| US-20130267538-A1 | TREATMENT OF MITOCHONDRIAL DISEASES | NLN, FH, MFN2 | ALOX5 1604/4885PTGS1 2790/4885PTGS2 2651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.